Exelixis | EXEL

Peers Price Chg Day Year Date
4502 Takeda 4,087.00 -6.00 -0.15% -9.30% Apr/26
4523 Eisai 6,240.00 -19.00 -0.30% -19.52% Apr/26
ACAD Acadia Pharmaceuticals 16.32 -0.27 -1.63% -19.65% Apr/25
AGIO Agios Pharmaceuticals 31.67 0 0% 43.30% Apr/25
AMGN Amgen 269.42 -3.72 -1.36% 12.82% Apr/25
AZN AstraZeneca 11,970.00 -56.00 -0.47% 1.48% Apr/26
BAYN Bayer 27.37 0.47 1.75% -54.18% Apr/26
BMRN BioMarin Pharmaceutical 82.17 -9.07 -9.94% -11.65% Apr/25
BMY Bristol-Myers Squibb 44.70 -4.16 -8.51% -34.28% Apr/25
CYTK Cytokinetics 64.84 -1.98 -2.96% 74.58% Apr/25
EXEL Exelixis 23.53 -0.18 -0.76% 27.53% Apr/25
GEN Genmab 1,961.00 45.50 2.38% -29.26% Apr/26
GSK Glaxosmithkline 40.91 0.05 0.12% 13.86% Apr/25
INCY Incyte 51.16 -0.62 -1.20% -30.43% Apr/25
IONS Ionis Pharmaceuticals 41.81 -0.65 -1.53% 16.95% Apr/25
LLY Eli Lilly 729.01 -8.11 -1.11% 93.75% Apr/25
MGNX MacroGenics 14.37 -1.33 -8.47% 110.70% Apr/25
MRK Merck 130.49 3.59 2.83% 15.04% Apr/25
MRNA Moderna 106.22 -2.79 -2.56% -18.75% Apr/25
NBIX Neurocrine Biosciences 137.73 -1.24 -0.89% 34.08% Apr/25
NOVN Novartis 89.35 -0.65 -0.72% -2.19% Apr/26
PFE Pfizer 25.26 -0.97 -3.69% -34.61% Apr/25
RARE Ultragenyx Pharmaceutical 43.85 -0.41 -0.93% 3.59% Apr/25
SNY Sanofi 49.33 2.77 5.95% -12.26% Apr/25
XNCR Xencor 19.23 0.21 1.10% -28.51% Apr/25

Indexes Price Day Year Date
CCMP USND 15612 -100.99 -0.64% 31.70% Apr/25
RTY US2000 1981 -14.31 -0.72% 13.13% Apr/26
MID US400 2887 -13.99 -0.48% 18.79% Apr/25

Exelixis traded at $23.53 this Thursday April 25th, decreasing $0.18 or 0.76 percent since the previous trading session. Looking back, over the last four weeks, Exelixis lost 0.34 percent. Over the last 12 months, its price rose by 27.53 percent. Looking ahead, we forecast Exelixis to be priced at 23.28 by the end of this quarter and at 21.97 in one year, according to Trading Economics global macro models projections and analysts expectations.

Exelixis, Inc. is an oncology focused biotechnology company. The Company is engaged in the discovery, development and commercialization of medicines to treat cancers. Its platform also provides therapies to cancer patients with additional treatment options. The Company's cabozantinib molecule, is an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET. The products derived from cabozantinib are CABOMETYX tablets for renal cell carcinoma (RCC) and COMETRIQ capsules for progressive, metastatic medullary thyroid cancer (MTC). Its other two product candidates are COTELLIC (cobimetinib), is an inhibitor of MEK with multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO (esaxerenone), is an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR) for the treatment of hypertension. Its phase I b clinical trial programs include XL092, STELLAR-001 and STELLAR-002.